Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Bioequivalence of Two Lispro Formulations
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Insulin lispro ADrug: Insulin lispro B
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 41
- Registration Number
- NCT01133392
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore
A Study in Erectile Dysfunction
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 623
- Registration Number
- NCT01130532
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saskatoon, Saskatchewan, Canada
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
- Conditions
- Nonarteritic Anterior Ischemic Optic Neuropathy
- Interventions
- Drug: PDE5 Inhibitors
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 345
- Registration Number
- NCT01131104
- Locations
- 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States
🇺🇸University of Miami School of Medicine, Miami, Florida, United States
🇺🇸Neuro-Ophthalmic Services, Royal Oak, Michigan, United States
A Long-Term, Open-Label, Study on Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2010-05-25
- Last Posted Date
- 2013-01-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1210
- Registration Number
- NCT01129674
- Locations
- 🇺🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vinnytsya, Ukraine
A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2012-11-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 23
- Registration Number
- NCT01127646
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1457
- Registration Number
- NCT01127633
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Camberwell, London, United Kingdom
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 807
- Registration Number
- NCT01126580
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nottingham, United Kingdom
A Study in Patients With Erectile Dysfunction
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2012-10-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 770
- Registration Number
- NCT01122264
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plymouth, Devon, United Kingdom
A Study of Duloxetine in Elderly Generalized Anxiety Disorder
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2013-09-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 291
- Registration Number
- NCT01118780
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chesterfield, United Kingdom
A Study of IMC-RON8 in Advanced Solid Tumors
- Conditions
- Cancer
- Interventions
- Biological: IMC-RON8
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 39
- Registration Number
- NCT01119456
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, New York, New York, United States